Central nervous system involvement in Anderson-Fabry disease: A clinical and MRI retrospective study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 11, 2008, Pages 1249-1254

  Buechner, Susanne ^a   Moretti, M ^b   Burlina, A P ^c   Cei, G ^d   Manara, R ^c   Ricci, R ^e   Mignani, R ^f   Parini, R ^g   Di Vito, R ^h   Giordano, G P ^b   Simonelli, P ^b   Siciliano, G ^d   Borsini, W ^b  

^a Regional Hospital Bozen   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f Infermi Hospital   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h Bernabeo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEMANGIOKERATOMA; HUMAN; ITALY; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; MALE; MONITORING; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; STROKE; BRAIN; DISEASE COURSE; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGE OF ONSET; BRAIN; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 55249121867     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.143693     Document Type: Article

References (34)

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. VIII ed. New York: The Mc-Graw-Hill Companies, 2001;3733-74.
2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75.
3. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24.
4. Deegan PB, Baehner AF, Barba Romero MA, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347-52.
5. Kaye EM, Kolodny EH, Logigian EL, et al. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505-9.
6. Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 2005;29:1-7.
7. Grewal RP. Stroke in Fabry's disease. J Neurol 1994;241:153-6.
8. Mitsias P, Levine S. Cerebrovascular complications of Fabry disease. Ann Neurol 1996;40:8-17.
9. Mohanraj R, Leach JP, Broome JC, et al. Neurological presentation of Fabry's disease in a 52 years old man. J Neurol Neurosurg Psychiatry 2002;73:340-2.
10. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-9.
11. Moore DF, Kaneski CR, Askari H, et al. The cerebral vasculopathy of Fabry Disease. J Neurol Sci 2007;257:258-63.
12. Puccio D, Coppola G, Corrado E, et al. Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease. Int Angiol 2005;24:295-9.
13. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005;64:2148-50.
14. Moore DF, Altarescu G, Ling GSF, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31.
15. Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251:564-70.
16. Mehta A, Ginsberg L, FOS investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005;94:24-7.
17. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-633.
18. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005;96:842-6.
19. Ginsberg L, Manara R, Valentine AR, et al. Magnetic resonance imaging changes in Fabry disease. Acta Paediatrica Suppl 2006;451:57-62.
20. Lidove O, Klein I, Lelièvre JD, et al. Imaging Features of Fabry disease. AJR 2006;186:1184-91.
21. Moore DF, Frank Y, Schiffmann R, et al. Increased signal intensity in the pulvinar on T1-weighted images: A pathognomonic MR Imaging sign of Fabry disease. Am J Neuroradiol 2003;24:1096-101.
22. Eng CM, Guffon N, Wilcox WR, et al. International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
23. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
24. Rankin J. Cerebral vascular accidents in patients over the age of 60. I. General considerations. II. Prognosis. II. Diagnosis and treatment. Scott Med J 1957;2(4-5).
25. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
26. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Neuroradiol 1987;8:421-6.
27. Fellgiebel A, Muller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600-2.
28. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
29. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
30. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-6.
31. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriosclerosis. J Neurol Neurosurg Psychiatry 2002;72:576-82.
32. Jardim L, Vedolini L, Schwartz IVD, et al. CNS involvement in Fabry disease: Clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004;27:229-40.
33. Jardim LB, Aesse F, Vedolin LM, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy. A 2-year follow-up. Arq Neuropsiquiatr 2006;64:711-7.
34. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of ERT for FD. Am J Hum Genet 2004;75:65-74.